CZ20032060A3 - Farmaceutický prostředek - Google Patents

Farmaceutický prostředek Download PDF

Info

Publication number: CZ20032060A3
Authority: CZ; Czechia
Prior art keywords: compound; nerve; injury; formula; spinal cord
Prior art date: 2000-12-29

Application number

CZ20032060A

Other languages

Czech (cs)

English (en)

Inventor

Nobuya Matsuoka

Takayuki Yamaji

Bruce Gold

Original Assignee

Fujisawa Pharmaceutical Co., Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-29

Filing date

2001-12-31

Publication date

2004-01-14

2001-12-31 Application filed by Fujisawa Pharmaceutical Co., Ltd filed Critical Fujisawa Pharmaceutical Co., Ltd

2004-01-14 Publication of CZ20032060A3 publication Critical patent/CZ20032060A3/cs

Links

239000000825 pharmaceutical preparation Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 69
230000006378 damage Effects 0.000 claims abstract description 33
208000027418 Wounds and injury Diseases 0.000 claims abstract description 25
208000014674 injury Diseases 0.000 claims abstract description 25
230000000508 neurotrophic effect Effects 0.000 claims abstract description 16
230000004064 dysfunction Effects 0.000 claims abstract description 10
230000001537 neural effect Effects 0.000 claims abstract description 5
238000000034 method Methods 0.000 claims description 26
210000004027 cell Anatomy 0.000 claims description 23
230000008929 regeneration Effects 0.000 claims description 22
238000011069 regeneration method Methods 0.000 claims description 22
239000000203 mixture Substances 0.000 claims description 16
210000005036 nerve Anatomy 0.000 claims description 16
210000002569 neuron Anatomy 0.000 claims description 15
210000000278 spinal cord Anatomy 0.000 claims description 15
210000000578 peripheral nerve Anatomy 0.000 claims description 14
208000028389 Nerve injury Diseases 0.000 claims description 13
239000008194 pharmaceutical composition Substances 0.000 claims description 13
239000003981 vehicle Substances 0.000 claims description 13
230000008764 nerve damage Effects 0.000 claims description 12
201000001119 neuropathy Diseases 0.000 claims description 12
230000007823 neuropathy Effects 0.000 claims description 12
208000033808 peripheral neuropathy Diseases 0.000 claims description 12
208000024827 Alzheimer disease Diseases 0.000 claims description 11
206010029240 Neuritis Diseases 0.000 claims description 11
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 11
210000003050 axon Anatomy 0.000 claims description 11
208000020431 spinal cord injury Diseases 0.000 claims description 11
108010025020 Nerve Growth Factor Proteins 0.000 claims description 10
230000012010 growth Effects 0.000 claims description 10
102000015336 Nerve Growth Factor Human genes 0.000 claims description 9
239000000463 material Substances 0.000 claims description 9
208000005987 polymyositis Diseases 0.000 claims description 9
208000032131 Diabetic Neuropathies Diseases 0.000 claims description 7
208000018737 Parkinson disease Diseases 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 7
208000011580 syndromic disease Diseases 0.000 claims description 7
239000004480 active ingredient Substances 0.000 claims description 6
238000002512 chemotherapy Methods 0.000 claims description 6
230000001965 increasing effect Effects 0.000 claims description 6
230000004936 stimulating effect Effects 0.000 claims description 6
208000023105 Huntington disease Diseases 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
230000005709 nerve cell growth Effects 0.000 claims description 5
230000006764 neuronal dysfunction Effects 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
238000001356 surgical procedure Methods 0.000 claims description 5
206010027910 Mononeuritis Diseases 0.000 claims description 4
206010036105 Polyneuropathy Diseases 0.000 claims description 4
206010037779 Radiculopathy Diseases 0.000 claims description 4
206010039966 Senile dementia Diseases 0.000 claims description 4
201000004810 Vascular dementia Diseases 0.000 claims description 4
239000006285 cell suspension Substances 0.000 claims description 4
230000001413 cellular effect Effects 0.000 claims description 4
230000001939 inductive effect Effects 0.000 claims description 4
208000013734 mononeuritis simplex Diseases 0.000 claims description 4
201000005518 mononeuropathy Diseases 0.000 claims description 4
201000006417 multiple sclerosis Diseases 0.000 claims description 4
208000019629 polyneuritis Diseases 0.000 claims description 4
230000002265 prevention Effects 0.000 claims description 4
239000012453 solvate Substances 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
102000008186 Collagen Human genes 0.000 claims description 2
108010035532 Collagen Proteins 0.000 claims description 2
229920001436 collagen Polymers 0.000 claims description 2
229920000609 methyl cellulose Polymers 0.000 claims description 2
239000001923 methylcellulose Substances 0.000 claims description 2
239000002243 precursor Substances 0.000 claims description 2
230000001737 promoting effect Effects 0.000 claims description 2
239000007952 growth promoter Substances 0.000 claims 4
230000001900 immune effect Effects 0.000 claims 2
230000001575 pathological effect Effects 0.000 claims 2
230000000472 traumatic effect Effects 0.000 claims 2
206010061218 Inflammation Diseases 0.000 claims 1
208000032984 Intraoperative Complications Diseases 0.000 claims 1
210000005013 brain tissue Anatomy 0.000 claims 1
230000010261 cell growth Effects 0.000 claims 1
238000000151 deposition Methods 0.000 claims 1
230000004054 inflammatory process Effects 0.000 claims 1
229940053128 nerve growth factor Drugs 0.000 claims 1
239000000651 prodrug Substances 0.000 claims 1
229940002612 prodrug Drugs 0.000 claims 1
230000008733 trauma Effects 0.000 claims 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 abstract description 21
230000001506 immunosuppresive effect Effects 0.000 abstract description 10
229940125890 compound Ia Drugs 0.000 description 30
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 23
241000700159 Rattus Species 0.000 description 20
229960001967 tacrolimus Drugs 0.000 description 19
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 19
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
238000007920 subcutaneous administration Methods 0.000 description 13
210000002241 neurite Anatomy 0.000 description 11
230000000694 effects Effects 0.000 description 10
210000003414 extremity Anatomy 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
238000011156 evaluation Methods 0.000 description 7
238000007619 statistical method Methods 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
239000000969 carrier Substances 0.000 description 5
201000010099 disease Diseases 0.000 description 5
239000002609 medium Substances 0.000 description 5
210000003497 sciatic nerve Anatomy 0.000 description 5
238000012360 testing method Methods 0.000 description 5
206010029260 Neuroblastoma Diseases 0.000 description 4
102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 4
108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
210000002683 foot Anatomy 0.000 description 4
210000004295 hippocampal neuron Anatomy 0.000 description 4
210000003141 lower extremity Anatomy 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
230000009471 action Effects 0.000 description 3
-1 for example Substances 0.000 description 3
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 3
229960003132 halothane Drugs 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
230000014511 neuron projection development Effects 0.000 description 3
230000001172 regenerating effect Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
239000012064 sodium phosphate buffer Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010016648 Immunophilins Proteins 0.000 description 2
102000000521 Immunophilins Human genes 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
208000025966 Neurological disease Diseases 0.000 description 2
108090000099 Neurotrophin-4 Proteins 0.000 description 2
238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 2
239000013543 active substance Substances 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
238000010171 animal model Methods 0.000 description 2
210000005056 cell body Anatomy 0.000 description 2
206010008118 cerebral infarction Diseases 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
210000001624 hip Anatomy 0.000 description 2
230000000971 hippocampal effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
238000007491 morphometric analysis Methods 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
230000009689 neuronal regeneration Effects 0.000 description 2
230000002981 neuropathic effect Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000005022 packaging material Substances 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000013222 sprague-dawley male rat Methods 0.000 description 2
238000010972 statistical evaluation Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
210000003371 toe Anatomy 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
206010008111 Cerebral haemorrhage Diseases 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010013710 Drug interaction Diseases 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
241000283086 Equidae Species 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010016880 Folate deficiency Diseases 0.000 description 1
208000010188 Folic Acid Deficiency Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000027530 Meniere disease Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
102000006386 Myelin Proteins Human genes 0.000 description 1
108010083674 Myelin Proteins Proteins 0.000 description 1
102000007072 Nerve Growth Factors Human genes 0.000 description 1
108090000742 Neurotrophin 3 Proteins 0.000 description 1
102100029268 Neurotrophin-3 Human genes 0.000 description 1
102000003683 Neurotrophin-4 Human genes 0.000 description 1
102100033857 Neurotrophin-4 Human genes 0.000 description 1
241000458112 Nonarthra tibialis Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
208000010886 Peripheral nerve injury Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
206010041591 Spinal osteoarthritis Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
108010085012 Steroid Receptors Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
229940117913 acrylamide Drugs 0.000 description 1
150000003926 acrylamides Chemical class 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
238000002266 amputation Methods 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
208000030137 articulation disease Diseases 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
208000036319 cervical spondylosis Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
210000001787 dendrite Anatomy 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
210000000256 facial nerve Anatomy 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000011888 foil Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
238000011990 functional testing Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
201000005442 glossopharyngeal neuralgia Diseases 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
238000009940 knitting Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000002684 laminectomy Methods 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229910052919 magnesium silicate Inorganic materials 0.000 description 1
235000019792 magnesium silicate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000007659 motor function Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
201000006938 muscular dystrophy Diseases 0.000 description 1
210000005012 myelin Anatomy 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000009251 neurologic dysfunction Effects 0.000 description 1
208000015015 neurological dysfunction Diseases 0.000 description 1
230000007514 neuronal growth Effects 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
231100000618 neurotoxin Toxicity 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
208000030212 nutrition disease Diseases 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000004248 oligodendroglia Anatomy 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229910000489 osmium tetroxide Inorganic materials 0.000 description 1
239000012285 osmium tetroxide Substances 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
239000003209 petroleum derivative Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical class OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000002574 poison Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
201000008752 progressive muscular atrophy Diseases 0.000 description 1
230000005855 radiation Effects 0.000 description 1
210000004116 schwann cell Anatomy 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000002356 single layer Substances 0.000 description 1
208000002320 spinal muscular atrophy Diseases 0.000 description 1
208000005801 spondylosis Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
102000005969 steroid hormone receptors Human genes 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
206010044652 trigeminal neuralgia Diseases 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
208000002670 vitamin B12 deficiency Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Psychology (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Packages (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Saccharide Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

CZ20032060A 2000-12-29 2001-12-31 Farmaceutický prostředek CZ20032060A3 (cs)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US25850000P	2000-12-29	2000-12-29

Publications (1)

Publication Number	Publication Date
CZ20032060A3 true CZ20032060A3 (cs)	2004-01-14

Family

ID=22980816

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CZ20032060A CZ20032060A3 (cs)	2000-12-29	2001-12-31	Farmaceutický prostředek

Country Status (18)

Country	Link
EP (1)	EP1353671A4 (ko)
JP (1)	JP2004527472A (ko)
KR (2)	KR20070030331A (ko)
CN (1)	CN1293877C (ko)
AR (1)	AR035411A1 (ko)
AU (1)	AU2002231277B2 (ko)
BR (1)	BR0116762A (ko)
CA (1)	CA2433384A1 (ko)
CZ (1)	CZ20032060A3 (ko)
HU (1)	HUP0302521A3 (ko)
IL (1)	IL156664A0 (ko)
MX (1)	MXPA03005941A (ko)
NO (1)	NO20032913D0 (ko)
NZ (1)	NZ527209A (ko)
PL (1)	PL366301A1 (ko)
RU (1)	RU2288716C2 (ko)
WO (1)	WO2002053159A1 (ko)
ZA (1)	ZA200305806B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003901023A0 (en) *	2003-03-04	2003-03-20	Fujisawa Pharmaceutical Co., Ltd.	New use
EP1706117A1 (en) *	2004-01-20	2006-10-04	Astellas Pharma Inc.	Method for treating erectile dysfunction
EP1810675A1 (en) *	2006-01-18	2007-07-25	Institut Curie	Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421
JP2009102226A (ja) *	2006-02-14	2009-05-14	Meiji Milk Prod Co Ltd	脊髄損傷治療剤
US9149459B2 (en)	2008-07-23	2015-10-06	Novartis Ag	Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
JP2015511242A (ja) *	2012-02-23	2015-04-16	インセルム（インスティチュートナショナルデラサンテエデラリシェルシェメディカル）	病変性前庭障害の治療に使用するカルシニューリン阻害剤
GB201309375D0 (en) *	2013-05-24	2013-07-10	Chronos Therapeutics Ltd	Medical methods and compounds for medical use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US537663A (en) *		1895-04-16		wubstee
ATE120466T1 (de) *	1987-12-09	1995-04-15	Fisons Plc	Makrozyklische verbindungen.
GR1001225B (el) *	1989-09-14	1993-06-30	Fisons Plc	Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
US5534520A (en) *	1990-04-10	1996-07-09	Fisher; Abraham	Spiro compounds containing five-membered rings
US5541193A (en) *	1991-09-05	1996-07-30	Abbott Laboratories	Heterocycle-containing macrocyclic immunomodulators
GB9202196D0 (en) *	1992-02-01	1992-03-18	Fisons Plc	Method of treatment
GB9218027D0 (en) *	1992-08-25	1992-10-14	Fisons Plc	Novel method of treatment
US5696135A (en) *	1995-06-07	1997-12-09	Gpi Nil Holdings, Inc.	Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5968921A (en) *	1997-10-24	1999-10-19	Orgegon Health Sciences University	Compositions and methods for promoting nerve regeneration
GB9917158D0 (en) *	1999-07-21	1999-09-22	Fujisawa Pharmaceutical Co	New use

2001
- 2001-12-27 AR ARP010106058A patent/AR035411A1/es unknown
- 2001-12-31 MX MXPA03005941A patent/MXPA03005941A/es active IP Right Grant
- 2001-12-31 WO PCT/US2001/050419 patent/WO2002053159A1/en not_active Ceased
- 2001-12-31 NZ NZ527209A patent/NZ527209A/en unknown
- 2001-12-31 AU AU2002231277A patent/AU2002231277B2/en not_active Ceased
- 2001-12-31 PL PL01366301A patent/PL366301A1/xx not_active Application Discontinuation
- 2001-12-31 KR KR1020077003889A patent/KR20070030331A/ko not_active Ceased
- 2001-12-31 RU RU2003123493/15A patent/RU2288716C2/ru not_active IP Right Cessation
- 2001-12-31 CA CA002433384A patent/CA2433384A1/en not_active Abandoned
- 2001-12-31 BR BR0116762-6A patent/BR0116762A/pt not_active Application Discontinuation
- 2001-12-31 CN CNB018228860A patent/CN1293877C/zh not_active Expired - Fee Related
- 2001-12-31 EP EP01991558A patent/EP1353671A4/en not_active Withdrawn
- 2001-12-31 JP JP2002554109A patent/JP2004527472A/ja not_active Ceased
- 2001-12-31 IL IL15666401A patent/IL156664A0/xx unknown
- 2001-12-31 HU HU0302521A patent/HUP0302521A3/hu unknown
- 2001-12-31 KR KR1020037008787A patent/KR100794204B1/ko not_active Expired - Fee Related
- 2001-12-31 CZ CZ20032060A patent/CZ20032060A3/cs unknown
2003
- 2003-06-24 NO NO20032913A patent/NO20032913D0/no not_active Application Discontinuation
- 2003-07-28 ZA ZA2003/05806A patent/ZA200305806B/en unknown

Also Published As

Publication number	Publication date
BR0116762A (pt)	2004-08-10
RU2003123493A (ru)	2005-01-20
NO20032913D0 (no)	2003-06-24
EP1353671A4 (en)	2004-07-14
KR20040007431A (ko)	2004-01-24
CN1538843A (zh)	2004-10-20
PL366301A1 (en)	2005-01-24
HUP0302521A3 (en)	2007-03-28
KR100794204B1 (ko)	2008-01-14
AR035411A1 (es)	2004-05-26
KR20070030331A (ko)	2007-03-15
JP2004527472A (ja)	2004-09-09
CA2433384A1 (en)	2002-07-11
ZA200305806B (en)	2005-01-26
AU2002231277B2 (en)	2006-11-30
RU2288716C2 (ru)	2006-12-10
HUP0302521A2 (hu)	2003-11-28
NZ527209A (en)	2005-09-30
CN1293877C (zh)	2007-01-10
IL156664A0 (en)	2004-01-04
MXPA03005941A (es)	2005-02-14
WO2002053159A1 (en)	2002-07-11
EP1353671A1 (en)	2003-10-22

Publication	Publication Date	Title
DE60316798T2 (de)	2008-07-24	Zusammensetzungen und verfahren zur behandlung von diabetes
KR100298808B1 (ko)	2001-11-22	외상손상과관련된신경학적병변의치료를위한,릴루졸을포함하는제약학적조성물
CA2044853C (en)	2004-11-09	Method for treating parkinson's disease employing an atp-sensitive potassium channel blocker
Mentis et al.	1993	Motoneurons destined to die are rescued by blocking N-methyl-D-aspartate receptors by MK-801
Geisler et al.	1992	GM-1 ganglioside in human spinal cord injury
HU217543B (hu)	2000-02-28	Eljárás perifériás neuropátia kezelésére és megelőzésére alkalmas gyógyászati készítmények előállítására, valamint inzulinszerű növekedési faktor I-et és kemoterápiás szert tartalmazó gyógyászati készítmények
JP5243428B2 (ja)	2013-07-24	神経細胞の損傷を減少させるための薬学的組成物
CN1228024A (zh)	1999-09-08	K－252a衍生物用于治疗外周或中枢神经系统疾病以及细胞因子超量生产的用途
Letechipı́a-Vallejo et al.	2001	Neuroprotective effect of melatonin on brain damage induced by acute global cerebral ischemia in cats
DE69635754T2 (de)	2006-07-27	Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht-bypass invasiver eingriffe
CZ20032060A3 (cs)	2004-01-14	Farmaceutický prostředek
JP3623501B2 (ja)	2005-02-23	インターロイキン−１阻害化合物による神経病学的状態の治療
US6284771B1 (en)	2001-09-04	Method for treating schizophrenia
CA1248454A (en)	1989-01-10	Cytidyl diphosphocholine-drug composition and process
US5236932A (en)	1993-08-17	Method for treating Parkinson's disease employing quinine
EP0305181B1 (en)	1994-11-30	Ethyl-(+)-apovincaminate for treating demyelinization clinical patterns of autoimmune origin
WO2017057562A1 (ja)	2017-04-06	末梢神経障害又は脊髄損傷の治療剤及び／又は予防剤
AU2002231277A1 (en)	2003-01-23	Neurotrophic tacrolimus analogs
KR100195651B1 (ko)	1999-06-15	신경 손상 및 발작의 치료를 위한 nk-1 수용체 길항물질
US20040077676A1 (en)	2004-04-22	Neurotrophic tacrolimus analogs
DE60215525T2 (de)	2007-06-06	Kombination aus quetiapin und zolmitriptan
Schneider	1994	The therapeutic role of gangliosides in neurological disorders
CA2455896A1 (en)	2003-03-13	Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma
JP2009504636A (ja)	2009-02-05	血漿または血清を含む神経損傷治療用の医薬組成物
US20220362202A1 (en)	2022-11-17	Drug For Treating And Preventing Dementia